Orthofix International N.V. (NASDAQ:OFIX) CFO Rice Doug sold 7,353 shares of the firm’s stock in a transaction that occurred on Monday, September 11th. The shares were sold at an average price of $49.46, for a total transaction of $363,679.38. Following the completion of the sale, the chief financial officer now owns 44,743 shares in the company, valued at approximately $2,212,988.78. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Orthofix International N.V. (OFIX) traded down 1.56% during midday trading on Wednesday, reaching $48.73. 44,452 shares of the company’s stock traded hands. The stock has a market cap of $885.42 million, a P/E ratio of 114.12 and a beta of 0.22. The company’s 50-day moving average price is $47.23 and its 200-day moving average price is $42.73. Orthofix International N.V. has a 52-week low of $32.51 and a 52-week high of $50.40.

Orthofix International N.V. (NASDAQ:OFIX) last announced its earnings results on Monday, August 7th. The medical device company reported $0.42 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.41 by $0.01. The firm had revenue of $108.90 million during the quarter, compared to analyst estimates of $102.94 million. Orthofix International N.V. had a net margin of 1.88% and a return on equity of 9.96%. The company’s revenue for the quarter was up 4.6% compared to the same quarter last year. During the same period in the prior year, the business earned $0.41 EPS. On average, equities analysts predict that Orthofix International N.V. will post $1.56 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This news story was originally reported by Daily Political and is the sole property of of Daily Political. If you are accessing this news story on another domain, it was stolen and republished in violation of US and international trademark & copyright law. The original version of this news story can be accessed at https://www.dailypolitical.com/2017/09/13/insider-selling-orthofix-international-n-v-ofix-cfo-sells-7353-shares-of-stock.html.

Institutional investors have recently bought and sold shares of the company. Ameriprise Financial Inc. boosted its stake in shares of Orthofix International N.V. by 23.5% during the 1st quarter. Ameriprise Financial Inc. now owns 423,655 shares of the medical device company’s stock worth $16,162,000 after buying an additional 80,710 shares during the last quarter. Paradice Investment Management LLC acquired a new position in shares of Orthofix International N.V. during the 2nd quarter worth about $6,642,000. OppenheimerFunds Inc. acquired a new position in shares of Orthofix International N.V. during the 1st quarter worth about $305,000. Blair William & Co. IL acquired a new position in shares of Orthofix International N.V. during the 2nd quarter worth about $1,301,000. Finally, NorthCoast Asset Management LLC boosted its stake in shares of Orthofix International N.V. by 26.9% during the 2nd quarter. NorthCoast Asset Management LLC now owns 92,952 shares of the medical device company’s stock worth $4,320,000 after buying an additional 19,691 shares during the last quarter. Institutional investors own 94.43% of the company’s stock.

OFIX has been the topic of a number of recent research reports. Ladenburg Thalmann Financial Services initiated coverage on shares of Orthofix International N.V. in a report on Wednesday, June 14th. They set a “buy” rating and a $53.25 price target on the stock. SunTrust Banks, Inc. initiated coverage on shares of Orthofix International N.V. in a report on Tuesday, May 23rd. They set a “buy” rating and a $49.00 price target on the stock. Zacks Investment Research upgraded shares of Orthofix International N.V. from a “sell” rating to a “hold” rating in a report on Thursday, July 6th. BidaskClub lowered shares of Orthofix International N.V. from a “strong-buy” rating to a “buy” rating in a report on Tuesday, July 25th. Finally, BTIG Research initiated coverage on shares of Orthofix International N.V. in a report on Wednesday, June 21st. They set a “buy” rating and a $52.00 price target on the stock. Seven analysts have rated the stock with a buy rating, The stock presently has an average rating of “Buy” and an average price target of $52.75.

Orthofix International N.V. Company Profile

Orthofix International N.V. (Orthofix) is a global medical device company. The Company is focused on providing reconstructive and regenerative orthopedic and spine solutions to physicians. The company operates in four segments: BioStim, Biologics, Extremity Fixation and Spine Fixation. Its BioStim solutions products include Cervical-Stim, Spinal-Stim and Physio-Stim.

Receive News & Ratings for Orthofix International N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orthofix International N.V. and related companies with MarketBeat.com's FREE daily email newsletter.